Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 2,005 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Discrete Clear all

Conditions: Interparental Conflict, Child Mental Health
Interventions: Family COMPASS, Families in Transition (FIT); Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 88 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Infection, Human Immunodeficiency Virus
Interventions: Lamivudine, Sorbitol; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Influenza
Interventions: Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: PHA1A
Interventions: Zidebactam-Cefepime, Metronidazole, FEP-ZID; Drug
Lead sponsor: Wockhardt; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Acute Promyelocytic Leukemia
Interventions: NRX 195183 Soft Gelatin Capsule; Drug
Lead sponsor: NuRx Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Astigmatism, Refractive Errors
Interventions: Delefilcon A toric soft contact lens, Lehfilcon A toric soft contact lens, Lotrafilcon B toric soft contact lens, Verofilcon A toric soft contact lens; Device
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 7
States / cities: Los Angeles, California • Longwood, Florida • Maitland, Florida + 4 more

Conditions: Influenza
Interventions: FluMist® live, attenuated, intranasal seasonal influenza vaccine, Fluzone® inactivated influenza virus vaccine; Biological
Lead sponsor: Armed Forces Research Institute of Medical Sciences, Thailand; Government
Eligibility: 18 Years to 49 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 0
States / cities: Not listed

Conditions: Mental Health, Conflict
Interventions: Parent-child intervention, Self-study Intervention; Behavioral
Lead sponsor: University of Notre Dame; Other
Eligibility: 4 Years and older
Enrollment: 1,800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: Fort Wayne, Indiana • Indianapolis, Indiana • Notre Dame, Indiana

Conditions: Fracture Forearm, Pediatric ALL
Interventions: Tablet-based educational intervention; Behavioral
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 0 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Smoking
Interventions: Cycloserine, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Blood Flow Restriction Training, Betaine Supplementation
Interventions: Betaine, Placebo; Dietary Supplement · Other
Lead sponsor: Baylor University; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Waco, Texas

Conditions: Healthy Control Subjects
Interventions: (S)-[18F] FBFP or (R)-[18F]FBFP; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Substance Abuse, Mental Health, Educational Problems
Interventions: Bridges 4-week Program; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 10 Years to 15 Years
Enrollment: 664 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Colorectal Cancer
Interventions: Usual care, Clinic-focused intervention, Clinic- and patient-focused; Behavioral
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 50 Years to 75 Years
Enrollment: 5,066 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 3
States / cities: Detroit, Michigan • Albuquerque, New Mexico • Seattle, Washington

Conditions: Spinal Cord Injuries
Interventions: Synaptic Pairing Interval, Frequency, Bouts, Spacing, Exercise, SCAP plus Exercise; Procedure
Lead sponsor: Bronx VA Medical Center; Federal
Eligibility: 18 Years to 85 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: HIV Infections, Electronic Health Record, Primary Health Care
Interventions: EMC2 PrEP Educational Tool, Discrete Scheduling of a Dedicated PrEP Visit; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Recurrent Pericarditis
Interventions: Rilonacept, Placebo; Drug
Lead sponsor: Kiniksa Pharmaceuticals (UK), Ltd.; Industry
Eligibility: 12 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 12
States / cities: Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 9 more

Conditions: Metastatic Pancreatic Adenocarcinoma
Interventions: BBI608, Nab-paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, Fluorouracil, MM-398; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 12
States / cities: Phoenix, Arizona • Atlanta, Georgia • Fort Wayne, Indiana + 9 more

Conditions: Depressive Symptoms, Major Depressive Disorder, Recurrent, in Remission
Interventions: Be Mindful; Behavioral
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 65 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Acute Myeloid Leukemia
Interventions: Cytarabine, Daunorubicin, Etoposide, Clofarabine, CliniMACS; Drug · Device
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 7
States / cities: Palo Alto, California • San Diego, California • Chicago, Illinois + 4 more

Conditions: MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
Interventions: TVB-2640 25 mg (US), TVB-2640 50 mg (US), Placebo (US), TVB-2640 50 mg (China), Placebo (China), TVB-2640 75 mg (US); Drug
Lead sponsor: Sagimet Biosciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 12
States / cities: Chula Vista, California • Montclair, California • Sacramento, California + 9 more

Conditions: Hemorrhage, Cesarean Section
Interventions: Masimo Rainbow Pulse CO-oximeter; Device
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Pedal Fat Pad Atrophy
Interventions: Pedal Fat Grafting, Local anesthetic; Procedure · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Systemic Sclerosis, Systemic Lupus Erythematosus, Dermatomyositis, Juvenile Rheumatoid Arthritis, Autoimmune Diseases
Interventions: Stem Cell Transplantation, CD34 selection; Procedure · Device
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 2 Years to 18 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Pilot Study of an Interparental Conflict Intervention for Separating or Divorcing Parents

A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers

St. Jude Open Label H5 Trial

A Single-center, Open-label, Study Evaluating Safety and Pharmacokinetics of Single Doses of Zidebactam-Cefepime and Metronidazole Alone or in Combination.

Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia

Clinical Comparison of Toric Contact Lenses Fit Characteristics

Study of Seasonal Influenza Vaccine Against H5N1 Avian Influenza Virus

The Happy Families Project: Testing the Effectiveness of a Conflict Resolution Program for Families

Taking POSNA's OrthoKids to the People

The Effect of Cycloserine on Smoking Behavior in Nicotine Dependent Smokers

Potential Synergistic Effect of Combined Blood Flow Restriction Training and Betaine Supplementation on Skeletal Muscle

PET Imaging of the sigma1 Receptor in Healthy Adults

Optimizing a Drug Abuse Prevention Program for Dissemination

Evaluation of an Intervention to Increase Colorectal Cancer Screening in Primary Care Clinics

Finding the Best Combination of Brain and Spinal Cord Stimulation With Hand Training After Spinal Cord Injury

An Electronic Health Record-based Approach to Increase PrEP Knowledge and Uptake: the EMC2 PrEP Strategy

Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer

The Effects of the Be Mindful Intervention in Previously Depressed Individuals Experiencing Subclinical Symptoms

Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia

Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

Continuous Non-Invasive Measurement of Hemoglobin During Parturition

Fat Grafting for Pedal Fat Pad Atrophy

Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders